According to a new market report published by Lucintel, the future of the companion diagnostic market looks promising with opportunities in the pharmaceutical and biopharmaceutical companies and reference laboratories. The companion diagnostic market is expected to grow with a CAGR of 20% from 2019 to 2024. The major drivers for this market are improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence, and increasing collaborations and partnerships for companion diagnostic test development.
Within the companion diagnostic market, oncology and neurology are the major segment by indication. The oncology segment is the largest segment of the companion diagnostic market.
Polymerase chain reaction (PCR), immunohistochemistry (IHC), In situ hybridization (ISH), and next-generation sequencing are the major technology segment of the companion diagnostic market.
North America will remain the largest region over the forecast period due to increasing technological advancements aimed at developing companion diagnostic tests for new indications such as neurology, infectious diseases, and so on.
F. Hoffmann-La Roche, Agilent Technologies, Qiagen N.V., Thermo Fisher Scientific, Abbott Laboratories, Biomérieux, Danaher Corporation, Illumina ,Myriad Genetics, Arup Laboratories, Sysmex, Hologic, Almac Group, and Abnova are among the major manufacturers of companion diagnostic.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the companion diagnostic market by product and service, technology, indication, end use, and region. Lucintel has prepared a comprehensive research report titled " Companion Diagnostic Market 2019-2024: Trends, Forecast, and Opportunity Analysis". This Lucintel report serves as a catalyst for growth strategy as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes a forecast for the companion diagnostic market by product and service, technology, indication, end use, and region as follows:
By Product and Service [$M shipment analysis for 2013 – 2024]:
• Assays & Reagents
• Software & Services
By Technology [$M shipment analysis for 2013 – 2024]:
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• In Situ Hybridization (ISH)
• Next-generation Sequencing
• Other Technologies
By Indication [$M shipment analysis for 2013 – 2024]:
• Oncology
• Neurology
• Others
By End Use [$M shipment analysis for 2013 – 2024]:
• Pharmaceutical and Biopharmaceutical Companies
• Reference Lab
• Other End Users
By Region [$M shipment analysis for 2013 – 2024]:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
• Asia-Pacific
o China
o India
o Japan
• ROW
o Brazil
A report of more than 150 pages will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link…… or [email protected].
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.
This report addresses the following key questions:
Q.1. What are some of the most promising potential, high-growth opportunities for the companion diagnostics market by product & service (assays and reagents and software and services), technology (polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH) , next-generation sequencing, and other technologies), indication (oncology, neurology, others, and other indications), end use (pharmaceutical and biopharmaceutical companies, reference lab, and other end user), and region (North America, Europe, Asia-Pacific, and ROW)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which regions will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the drivers and challenges of the companion diagnostics market?
Q.5. What are the business risks and threats to the companion diagnostics market?
Q.6. What are emerging trends in this companion diagnostics market and the reasons behind them?
Q.7. What are some changing demands of customers in the companion diagnostics market?
Q.8. What are the new developments in the companion diagnostics market? Which companies are leading these developments?
Q.9. Who are the major players in this companion diagnostics market? What strategic initiatives are being implemented by key players for business growth?
Q.10. What are some of the competitive products and processes in this companion diagnostics area and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11. What M & A activities have taken place in the last 5 years in companion diagnostics market?